Intraductal Papilloma Market Research Report- Global Forecast till 2027

Intraductal Papilloma Market Information: By Type (Central/Solitary, Peripheral/Multiple), Diagnosis (Mammogram, Biopsy, Ultrasonography, Computerized Tomography (CT)), Treatment (Microdochectomy, Total Duct Excision), and End User - Global Forecast till 2027

ID: MRFR/Pharma/3039-HCR | February 2021 | Region: Global | 85 pages

Intraductal papilloma Market Overview


An intraductal papilloma is a benign, or noncancerous, breast tumour that forms in a milk duct and is made of gland and fibrous tissue as well as blood vessels. These generally appear as lumps after breast examination and may cause nipple discharge or bleeding. Intraductal papilloma most commonly occur in women between ages 35 and 55. Central/solitary papillomas are generally benign while multiple papillomas, have been associated with a slightly higher risk of breast cancer.


The symptoms of intraductal papilloma are breast enlargement, inversion of the nipple, thickening or swelling of part of the breast, changes to the breast or nipple skin area, such as dimpling, redness, scaling, peeling etc. Multiple papillomas consist of about 10 % of all intraductal papillomas. Intraductal papilloma comprise approximately 10% of all benign breast tumour types and are benign lesions with an incidence of approximately 2-3% in humans. Risk factors such as obesity, alcohol consumption, postmenopausal hormone therapy, having the first child after the age of 35, or never having a child, medications containing estrogen and progesterone such as birth control pills, menstrual cycle abnormalities, physical inactivity, not breastfeeding the child etc. increase the chances of intraductal papillomas.


The market for intraductal papilloma Market is constrained by the lack of awareness, high cost of surgery, complications of the surgery, lack of focus on women health in the developing and poorer regions of the world etc. Market development represents the best strategy for the market growth. The market will witness exponential growth over the review period owing to minimal invasive surgeries procedures such as needle aspiration biopsy surgeries etc.


The intraductal papilloma market is expected to reach USD 8.4 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.


Research Methodology Intraductal Papilloma Market


Sources: Mayo Clinic, Healthline Media, MRFR Analysis


 


Intended Audience



  • Global intraductal papilloma treatment manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities


Figure 1          Global Intraductal Papilloma Market by Type, 2016 (%) Intraductal Papilloma Market-

Segments:


The intraductal papilloma market has been segmented on the basis of type, diagnosis, treatment, and end user.


Based on type, the Intraductal papilloma Market has been segmented as central/solitary papillomas, peripheral/multiple papillomas and others.


Based on diagnosis, the market has been segmented as examination, ultrasonography, biopsy, mammogram/galactography, ductograms, Computerized Tomography (CT) and others.


Based on surgery, the market has been segmented as microdochectomy, total duct excision, drugs and others.


Based on the end user, Intraductal papilloma Market has been segmented as hospitals & clinics, academic and research, and others.


Regional Analysis


The Americas account for a significant market share owing to extensive volume of surgeries performed and high expenditure on the health care. Additionally, the fastest uptake of new products and surgical procedures in the US drive the intraductal papilloma market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger insurance penetration is adding fuel to Intraductal papilloma Market growth. Moreover, the US spends high on its healthcare, which accounts for 16% of GDP, further cruising the market for intraductal papilloma treatment.


Europe is the second largest market in the world due to high income and strong healthcare penetration. European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period.


Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asian countries such as Vietnam, Thailand, and Malaysia are projected to contribute highly to the market growth.


Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.


Key Players in the Intraductal papilloma Market


Some of key players profiled in the report are Allergen plc, Teva Pharmaceutical Industries Ltd., Mylan Pharmaceuticals Inc., Entax Medical, Olympus, Boston Scientific Corporation, Medtronic, Cook Medical, Cook Medical, Inc., and others.



Frequently Asked Questions (FAQ) :


Intraductal Papilloma Market valuation would be USD8.4 Bn by 2023.

Intraductal Papilloma Market CAGR would be 4.4% during the forecast period.

The Americas would dominate the Intraductal Papilloma Market.

The fastest-growing Intraductal Papilloma Market in Europe would be the UK.

The Intraductal Papilloma Market players would be Teva Pharmaceutical Industries Ltd., Allergen plc, Entax Medical, Mylan Pharmaceuticals Inc., Boston Scientific Corporation, Cook Medical, Inc., Medtronic, Cook Medical, Olympus, and others.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Intraductal Papilloma Market, by Types

6.1 Introduction

6.2 Pseudomembranous

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Erythematous

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Hyperplastic

6.4.1 Market Estimates & Forecast, 2020-2027

6.5 Others

6.5.1 Market Estimates & Forecast, 2020-2027

7. Global Intraductal Papilloma Market, by Diagnosis

7.1 Introduction

7.2 Examination

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Biopsy

7.3.1 Market Estimates & Forecast, 2020-2027

7.4 Endoscopy

7.4.1 Market Estimates & Forecast, 2020-2027

7.5 Others

7.5.1 Market Estimates & Forecast, 2020-2027

8. Global Intraductal Papilloma Market, by Treatment

8.1 Introduction

8.2 Anti-Fungal

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Immune-Modulators

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Others

8.4.1 Market Estimates & Forecast, 2020-2027

9. Global Intraductal Papilloma Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

9.2.1 Market Estimates & Forecast, 2020-2027

9.3 Academic and Research Institutes

9.3.1 Market Estimates & Forecast, 2020-2027

9.4 Others

9.4.1 Market Estimates & Forecast, 2020-2027

10. Global Intraductal Papilloma Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 UK

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Bayer AG

12.1.1 Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 Key Developments

12.2 Teva Pharmaceuticals

12.2.1 Overview

12.2.2 Product Overview

12.2.3 Financials

12.2.4 Key Developments

12.3 Stellar Pharma

12.3.1 Overview

12.3.2 Product Overview

12.3.3 Financials

12.3.4 Key Development

12.4 Pfizer Inc.

12.4.1 Overview

12.4.2 Product Overview

12.4.3 Financials

12.4.4 Key Development

12.5 Wockhardt Ltd.

12.5.1 Overview

12.5.2 Product Overview

12.5.3 Financials

12.5.4 Key Development

12.6 Ranbaxy Laboratories Limited

12.6.1 Overview

12.6.2 Product Overview

12.6.3 Financials

12.6.4 Key Development

12.7 Bristol Laboratories

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Development

12.8 Glenmark Pharmaceuticals

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Development

12.9 GlaxoSmithKline Plc.

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Development

12.10 Others

12.10.1 Overview

12.10.2 Product Overview

12.10.3 Financials

12.10.4 Key Development

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical Industry

14 Appendix

List of Tables

TABLE 1 GLOBAL INTRADUCTAL PAPILLOMA MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 2 PHYSICAL EXAMINATION FOR INTRADUCTAL PAPILLOMA MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 3 PSEUDOMEMBRANOUS FOR INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD

MILLION)

TABLE 4 ERYTHEMATOUS FOR INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD

MILLION)

TABLE 5 HYPERPLASTIC FOR INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 6 OTHERS FOR INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 7 GLOBAL INTRADUCTAL PAPILLOMA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 8 EXAMINATION FOR INTRADUCTAL PAPILLOMA MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 9 BIOPSY FOR INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 10 ENDOSCOPY FOR INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 11 OTHERS FOR INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 12 GLOBAL INTRADUCTAL PAPILLOMA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 13 ANTI-FUNGAL FOR INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 14 IMMUNE-MODULATORS FOR INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD

MILLION)

TABLE 15 OTHERS FOR INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 16 GLOBAL INTRADUCTAL PAPILLOMA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 17 NORTH AMERICA INTRADUCTAL PAPILLOMA MARKET, BY COUNTRY 2020-2027 (USD MILLION)

TABLE 18 NORTH AMERICA INTRADUCTAL PAPILLOMA MARKET, BY TYPE 2020-2027 (USD MILLION)

TABLE 19 NORTH AMERICA INTRADUCTAL PAPILLOMA MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

TABLE 20 NORTH AMERICA INTRADUCTAL PAPILLOMA MARKET, BY TREATMENT 2020-2027 (USD

MILLION)

TABLE 21 NORTH AMERICA INTRADUCTAL PAPILLOMA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 NORTH AMERICA INTRADUCTAL PAPILLOMA MARKET BY REGION 2020-2027 (USD MILLION

TABLE 23 EUROPE INTRADUCTAL PAPILLOMA MARKET BY COUNTRY 2020-2027 (USD MILLION)

TABLE 24 EUROPE INTRADUCTAL PAPILLOMA MARKET, BY TYPE 2020-2027 (USD MILLION)

TABLE 25 EUROPE INTRADUCTAL PAPILLOMA MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

TABLE 26 EUROPE INTRADUCTAL PAPILLOMA MARKET, BY TREATMENT 2020-2027 (USD MILLION)

TABLE 27 EUROPE INTRADUCTAL PAPILLOMA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 EUROPE INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 29 ASIA PACIFIC INTRADUCTAL PAPILLOMA MARKET BY COUNTRY 2020-2027 (USD MILLION)

TABLE 30 ASIA PACIFIC INTRADUCTAL PAPILLOMA MARKET, BY TYPE 2020-2027 (USD MILLION)

TABLE 31 ASIA PACIFIC INTRADUCTAL PAPILLOMA MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

TABLE 32 ASIA PACIFIC INTRADUCTAL PAPILLOMA MARKET, BY TREATMENT 2020-2027 (USD MILLION)

TABLE 33 ASIA PACIFIC INTRADUCTAL PAPILLOMA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 34 ASIA PACIFIC INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA INTRADUCTAL PAPILLOMA MARKET BY COUNTRY 2020-2027 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA INTRADUCTAL PAPILLOMA MARKET, BY TYPE 2020-2027 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA INTRADUCTAL PAPILLOMA MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA INTRADUCTAL PAPILLOMA MARKET, BY TREATMENT 2020-2027 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA INTRADUCTAL PAPILLOMA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA INTRADUCTAL PAPILLOMA MARKET, BY REGION 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET DYNAMICS FOR GLOBAL INTRADUCTAL PAPILLOMA MARKET

FIGURE 3 GLOBAL INTRADUCTAL PAPILLOMA MAKRET, BY SEGMENT, 2020

FIGURE 4 GLOBAL INTRADUCTAL PAPILLOMA SUCCESS MARKET, BY REGION

FIGURE 5 GLOBAL INTRADUCTAL PAPILLOMA MARKET SHARE, BY TYPE 2020

FIGURE 6 GLOBAL INTRADUCTAL PAPILLOMA MARKET SHARE, BY DIAGNOSIS 2020

FIGURE 7 GLOBAL INTRADUCTAL PAPILLOMA MARKET SHARE, BY TREATMENT, 2020

FIGURE 8 GLOBAL INTRADUCTAL PAPILLOMA MARKET SHARE, BY END USER, 2020

FIGURE 9 GLOBAL INTRADUCTAL PAPILLOMA MARKET SHARE, 2020

FIGURE 10 GLOBAL INTRADUCTAL PAPILLOMA MARKET SHARE, BY REGION, 2020

FIGURE 11 NORTH AMERICA INTRADUCTAL PAPILLOMA MARKET SHARE, BY COUNTRY, 2020

FIGURE 12 EUROPE INTRADUCTAL PAPILLOMA MARKET SHARE, BY COUNTRY, 2020

FIGURE 13 ASIA PACIFIC INTRADUCTAL PAPILLOMA MARKET SHARE, BY COUNTRY, 2020

FIGURE 14 MIDDLE EAST & AFRICA INTRADUCTAL PAPILLOMA MARKET, BY REGION, 2020

FIGURE 15 GLOBAL INTRADUCTAL PAPILLOMA MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 16 PFIZER INC.: KEY FINANCIALS

FIGURE 17 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 18 PFIZER INC.: GEOGRAPHICAL REVENUE

FIGURE 19 BAYER AG: KEY FINANCIALS

FIGURE 20 BAYER AG: SEGMENTAL REVENUE

FIGURE 21 BAYER AG: GEOGRAPHICAL REVENUE

FIGURE 22 GLENMARK PHARMACEUTICALS: KEY FINANCIALS

FIGURE 23 GLENMARK PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 24 GLENMARK PHARMACEUTICALS: GEOGRAPHICAL REVENUE

FIGURE 25 RANBAXY LABORATORIES LIMITED: KEY FINANCIALS

FIGURE 26 RANBAXY LABORATORIES LIMITED: SEGMENTAL REVENUE

FIGURE 27 RANBAXY LABORATORIES LIMITED: GEOGRAPHICAL REVENUE

FIGURE 28 GLAXOSMITHKLINE: FINANCIAL REVENUE

FIGURE 29 GLAXOSMITHKLINE: SEGMENTAL REVENUE

FIGURE 30 GLAXOSMITHKLINE: GEOGRPAHICAL REVENUE

FIGURE 31 WOCKHARDT LTD.: FINANCIAL REVENUE

FIGURE 32 WOCKHARDT LTD.: SEGMENTAL REVENUE

FIGURE 33 WOCKHARDT LTD.: GEOGRPAHICAL REVENUE